ISOPTIN SR 120 MG — DIN 01907123
VERAPAMIL HYDROCHLORIDE : 120 MG · BGP PHARMA ULC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is ISOPTIN SR?
ISOPTIN SR 120 MG contains VERAPAMIL HYDROCHLORIDE : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 01907123, held by BGP PHARMA ULC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Dec-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ISOPTIN SR used for?
Treatment of mild to moderate essential hypertension. Normally used when diuretics or beta-blockers are associated with unacceptable adverse effects or are contraindicated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Verapamil cost around the world?
Verapamil is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 15 | 19 | ZAR███.██ |
| United States | acquisition | 3 | 13 | USD███.██ |
| Australia | ex-manufacturer | 6 | 12 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 12 | 12 | EUR███.██ |
| Romania | max producer price | 5 | 6 | RON███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Slovakia | categorised final price | 5 | 5 | EUR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
81 pack listings across 59 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Verapamil pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Verapamil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Verapamil, across 53 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 5 | 2 | APO-VERAP SR, APO-VERAP TAB 80MG, APO-VERAP TABLET 120MG | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 8 | 1 | MYLAN-VERAPAMIL, MYLAN-VERAPAMIL SR | Sourceable in Canada |
| BGP PHARMA ULC | 3 | 1 | ISOPTIN SR | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | VERAPAMIL HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| NU-PHARM INC | 5 | 0 | NU-VERAP SR, NU-VERAP TAB 120MG, NU-VERAP TAB 80MG | No marketed DIN |
| PRO DOC LIMITEE | 5 | 0 | PRO-VERAPAMIL SR, VERAPAMIL TAB 80MG, VERAPAMIL-120 TAB | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 3 | 0 | ISOPTIN INJ 2.5MG/ML, ISOPTIN TAB 120MG, ISOPTIN TAB 80MG | No marketed DIN |
| PFIZER CANADA ULC | 3 | 0 | COVERA-HS, VERAPAMIL HYDROCHLORIDE INJECTION USP | No marketed DIN |
| RECRO GAINESVILLE LLC | 3 | 0 | VERELAN | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | NOVO-VERAMIL, NOVO-VERAMIL SR | No marketed DIN |
| PENTAPHARM LTD. | 2 | 0 | PENTA-VERAPAMIL - 120MG, PENTA-VERAPAMIL - 80MG | No marketed DIN |
| TARO PHARMACEUTICALS INC | 2 | 0 | TARO-VERAPAMIL TAB 120MG, TARO-VERAPAMIL TAB 80MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 120 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | 120 mg: Bottles of 100; 180 mg: Bottles of 100; 240 mg: Bottles of 100 and 500. |
| Storage | Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice for this form is usually 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Verapamil |
|---|---|
| ATC code | C08DA01 |
| AHFS class | 24:28.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01907123 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1907123 |
| Brand name | ISOPTIN SR |
| Generic / active ingredient | VERAPAMIL HYDROCHLORIDE : 120 MG |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Prescription |
| ATC code | C08DA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C08DA |
| Current status | MARKETED |
| Status date | 18-Dec-2017 |
| Original market date | 1991-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualize titration. Initial: 180-240 mg/day. Max: 480 mg/day. Take with food. Do not crush/chew. 240 mg tablet may be split. Lower doses (120 mg) may be warranted in elderly.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; complicated MI; severe LV dysfunction; cardiogenic shock; severe hypotension; 2nd/3rd degree AV block; sick sinus syndrome; bradycardia; WPW/LGL syndromes; use with ivabradine/flibanserin.
Warnings and precautions
Negative inotropic effect (avoid in heart failure); affects AV/SA nodes (conduction disturbances); caution in neuromuscular diseases (myasthenia gravis); monitor liver function.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 53 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-VERAP TAB 80MG | 80 MG | TABLET | APOTEX INC | MARKETED | 00782483 |
| APO-VERAP TABLET 120MG | 120 MG | TABLET | APOTEX INC | MARKETED | 00782491 |
| MYLAN-VERAPAMIL SR | 120 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02210347 |
| VERAPAMIL HYDROCHLORIDE INJECTION USP | 2.5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 02166739 |
| ALTI-VERAPAMIL - 120MG | 120 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00867373 |
| ALTI-VERAPAMIL - 80MG | 80 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00867365 |
| APO-VERAP SR | 120 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246893 |
| APO-VERAP SR | 180 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246894 |
| APO-VERAP SR | 240 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246895 |
| COVERA-HS | 180 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | CANCELLED POST MARKET | 02231676 |
2 · Same class — other molecules in ATC C08DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Verapamil | ALTI-VERAPAMIL - 120MG · ALTI-VERAPAMIL - 80MG · APO-VERAP SR · APO-VERAP TAB 80MG · +29 more | 53 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C08D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C08DB | Diltiazem | 175 | 75 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ISOPTIN SR called?
The same molecule, Verapamil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cordilox SR | Latin | Australia |
| FIBROCARD LP | Latin | Morocco |
| Isoptin | Latin | Australia |
| Isoptin ICHS retard | Latin | Slovakia |
| Sandoz Verapamil | Latin | South Africa |
| Vasomil Injection | Latin | South Africa |
| VeraHexal | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.